DAVIX – Dynamika’s novel endpoint for measuring proliferation of neointima
A collaboration between IAG and the University of Leeds:
The proprietary process name DAVIX is copyrighted by the University of Leeds, with a non exclusive life time licence assigned to IAG (Image Analysis Group).
Neointima proliferation results in vascular wall thickening and gradual loss of luminal patency and is a key pathological feature of Systemic Sclerosis (SSc). It is a recognised culprit pathological lesion in Digital Ulcers (DU), pulmonary hypertension and renal crisis.
DAVIX, Digital Artery Volume Index, describes an innovative time of flight MRI angiography, quantitatively assessing digital arterial blood flow without the need for contrast administration, predicting the onset of DUs in SSc patients.
DAVIX is being deployed by major biotech and pharmaceutical companies in global clinical trials involving over 100 sites around the world, to measure the degree to which digital blood flow is compromised and to be tested as surrogate outcome measure of SSC vascular disease activity .
“DAVIX is the first contrast free, MRI quantitative measure of vascular disease in SSc. Building on its predictive value for active vascular disease, in the context of observational cohorts, it is now tested in the context of randomised clinical trials as stratification tool for vascular disease and as surrogate endpoint for vasoactive interventions” said Professor Francesco Del Galdo, University of Leeds.
“IAG is delighted to have collaborated with the DAVIX development team.DAVIX fits perfectly with IAG’s suite of advanced AI supported imaging methodologies and endpoints that are being deployed across hundreds of globally distributed clinical sites, underpinned by DYNAMIKA, IAG’s proprietary secure cloud based medical image processing platform,“ said Dr Olga Kubassova, CEO, IAG (Image Analysis Group)
About Image Analysis Group (IAG)
IAG, Image Analysis Group is a unique partner to life sciences companies, leading AI-powered drug development and precision medicine. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.